Bayesian adaptive design of early-phase clinical trials for precision medicine based on cancer biomarkers

Yada Shinjo ()
Additional contact information
Yada Shinjo: Department of Clinical Biostatistics, Graduate School of Medicine, Kyoto University, Yoshida Konoe-cho, Sakyo-ku, Kyoto 606-8501, Japan

The International Journal of Biostatistics, 2022, vol. 18, issue 1, 109-125

Abstract: Cancer tissue samples obtained via biopsy or surgery were examined for specific gene mutations by genetic testing to inform treatment. Precision medicine, which considers not only the cancer type and location, but also the genetic information, environment, and lifestyle of each patient, can be applied for disease prevention and treatment in individual patients. The number of patient-specific characteristics, including biomarkers, has been increasing with time; these characteristics are highly correlated with outcomes. The number of patients at the beginning of early-phase clinical trials is often limited. Moreover, it is challenging to estimate parameters of models that include baseline characteristics as covariates such as biomarkers. To overcome these issues and promote personalized medicine, we propose a dose-finding method that considers patient background characteristics, including biomarkers, using a model for phase I/II oncology trials. We built a Bayesian neural network with input variables of dose, biomarkers, and interactions between dose and biomarkers and output variables of efficacy outcomes for each patient. We trained the neural network to select the optimal dose based on all background characteristics of a patient. Simulation analysis showed that the probability of selecting the desirable dose was higher using the proposed method than that using the naïve method.

Keywords: Bayesian inference; dose-finding; phase I/II clinical trial; precision medicine (search for similar items in EconPapers)
Date: 2022
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://doi.org/10.1515/ijb-2021-0009 (text/html)
For access to full text, subscription to the journal or payment for the individual article is required.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:bpj:ijbist:v:18:y:2022:i:1:p:109-125:n:2

Ordering information: This journal article can be ordered from
https://www.degruyter.com/journal/key/ijb/html

DOI: 10.1515/ijb-2021-0009

Access Statistics for this article

The International Journal of Biostatistics is currently edited by Antoine Chambaz, Alan E. Hubbard and Mark J. van der Laan

More articles in The International Journal of Biostatistics from De Gruyter
Bibliographic data for series maintained by Peter Golla ().